October 27, 2022
WHO’s new TB numbers highlight an emergency in need of action
Statement from Mel Spigelman, MD, President and CEO, TB Alliance
September 19, 2022
TB Alliance Board of Directors Appoints Two New Members
Kim Schwartz and Rasha Hibri are Welcomed to the Board
August 31, 2022
Drug-Resistant TB Trial Results Published in New England Journal of Medicine
Results of ZeNix Trial Show Effectiveness of BPaL Regimen for Highly Drug-Resistant TB Can Be Maintained with Reduced Dosing of Linezolid
August 17, 2022
PAN-TB Collaboration to Advance Investigational Tuberculosis Drug Regimens to Phase 2 Clinical Trials
Public-private collaboration to evaluate five antimicrobial agents across two combination regimens for treating both drug-susceptible and drug-resistant forms of TB with shorter treatment durations
June 1, 2022
TB Alliance Names Pietro Turilli as Head of External Affairs
Executive brings more than 20 years in global partnerships and resource mobilization
March 24, 2022
Advancing the Treatment of Drug-Resistant Tuberculosis this World TB Day
Imagining a TB-free world amidst resurgence during COVID-19 pandemic
March 11, 2022
Request for Proposals: Clinical Research Organization
February 2, 2022